 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «123» |
- | baxdrostat (CIN-107) / AstraZeneca
Enrollment closed, Trial primary completion date: spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) - Jul 3, 2023
P2, N=15, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Oct 2024
- || baxdrostat (CIN-107) / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - Jun 27, 2023
P2, N=300, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Oct 2024 Trial completion date: Aug 2024 --> Nov 2023 | Trial primary completion date: Aug 2024 --> Nov 2023
- | baxdrostat (CIN-107) / AstraZeneca
Journal: Baxdrostat for Treatment-Resistant Hypertension. Reply. (Pubmed Central) - May 14, 2023
Trial completion date: Aug 2024 --> Nov 2023 | Trial primary completion date: Aug 2024 --> Nov 2023 No abstract available
- | baxdrostat (CIN-107) / AstraZeneca
Journal: Baxdrostat for Treatment-Resistant Hypertension. (Pubmed Central) - May 14, 2023
No abstract available No abstract available
- | baxdrostat (CIN-107) / AstraZeneca
Journal: Baxdrostat for Treatment-Resistant Hypertension. (Pubmed Central) - May 14, 2023
No abstract available No abstract available
- | baxdrostat (CIN-107) / AstraZeneca
Journal: Baxdrostat for Treatment-Resistant Hypertension. (Pubmed Central) - May 14, 2023
No abstract available No abstract available
- | baxdrostat (CIN-107) / AstraZeneca
Trial completion date: spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) - May 11, 2023
P2, N=12, Recruiting, Sponsor: CinCor Pharma, Inc.
No abstract available Trial completion date: Aug 2023 --> Dec 2024
- || baxdrostat (CIN-107) / AstraZeneca
PK/PD data, Journal: Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. (Pubmed Central) - May 8, 2023
P1
Trial completion date: Aug 2023 --> Dec 2024 The results of this study suggest that diabetic patients with hypertension receiving both metformin and baxdrostat are unlikely to require dose adjustment.
- |||| baxdrostat (CIN-107) / AstraZeneca
Clinical: Finally get to see HALO trial data of baxdrostat, a null trial. Turns out that 20/54(36%) pts had undetected Baxdrostat levels. If data are limited to pts with + drug levels, ⬇️BP is seen. Drugs do not work if you don't take them ! Drug level is the 🔑 in HTN RCT. @AnandVaidya17 (Twitter) - May 5, 2023
- || baxdrostat (CIN-107) / AstraZeneca
Review, Journal: Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease. (Pubmed Central) - Mar 21, 2023
To the best of our knowledge, this is the first systematic review to summarize evidence-based articles relevant to the use of a novel drug (aldosterone synthase inhibitor) in the treatment of HTN and cardiovascular disease. Making the current database of relevant information on baxdrostat and other aldosterone synthase inhibitors readily available will, no doubt, aid physicians and other medical practitioners in their decision-making about employing aldosterone synthase inhibitors in the treatment of patients.
- ||| baxdrostat (CIN-107) / AstraZeneca
Clinical, Adherence: ICYMI: "36% of the 54 patients who completed the 8-week treatment in the 2 mg arm, had baxdrostat levels that were less than 0.2 ng/mL, indicating nonadherence. That level was less than 1% of the expected level" @DLBHATTMD @MountSinaiHeart #cardiotwitter https://t.co/JfbJ3v2PJN (Twitter) - Mar 17, 2023
- ||| baxdrostat (CIN-107) / AstraZeneca
Clinical, Adherence: ICYMI: "36% of the 54 patients who completed the 8-week treatment in the 2 mg arm, had baxdrostat levels that were less than 0.2 ng/mL, indicating nonadherence. That level was less than 1% of the expected level" @DLBHATTMD @MountSinaiHeart #cardiotwitter https://t.co/JfbJ3v2PJN (Twitter) - Mar 16, 2023
- ||||| baxdrostat (CIN-107) / AstraZeneca
Clinical, Adherence: Baxdrostat, an aldosterone synthase inhibitor, did not lower systolic BP compared with placebo at 8 weeks in patients with uncontrolled hypertension, but nonadherence may have been a factor @DLBHATTMD @MountSinaiHeart #cardiotwitter https://t.co/JfbJ3v2PJN (Twitter) - Mar 16, 2023
- ||| baxdrostat (CIN-107) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date: spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) - Mar 6, 2023
P2, N=12, Recruiting, Sponsor: CinCor Pharma, Inc.
Making the current database of relevant information on baxdrostat and other aldosterone synthase inhibitors readily available will, no doubt, aid physicians and other medical practitioners in their decision-making about employing aldosterone synthase inhibitors in the treatment of patients. N=18 --> 12 | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- ||| baxdrostat (CIN-107) / AstraZeneca
Clinical: Despite positive results of Baxdrostat for resistant HTN, HALO results did not reach significant difference in non RHTN (uncontrolled <3 drugs). The problem is the placebo had a large ⬇️ in BP while pts are on background therapy, which may not be constant https://t.co/yp9BFOHW8k (Twitter) - Mar 5, 2023
- ||| baxdrostat (CIN-107) / AstraZeneca
Clinical, Adherence, Discordant: 3/ Why the discordant effect? Large placebo effect in HALO (well-known in resistant HTN) ? poor adherence but K>6.0 was 5% (2mg) What now for baxdrostat? (Twitter) - Mar 5, 2023
- ||| baxdrostat (CIN-107) / AstraZeneca
Clinical, Compliance: #HALO trial comes up short for Baxdrostat in HTN by @DLBHATTMD at #ACC23. @NanetteWenger points out that Black patients remain largest untreated group in US, so new options ARE needed. Also, that taking pills out of a bottle & putting in a pill-sorter does not = compliance. (Twitter) - Mar 4, 2023
- ||||| baxdrostat (CIN-107) / AstraZeneca
Clinical: Up next at ACC/WCC: @DLBHATTMD of @MountSinaiNYC presented HALO results, noting that baxdrostat was safe, but not associated with a significant reduction of seated SBP among patients with uncontrolled #hypertension #ACC23 #WCCardio @ACCmediacenter (Twitter) - Mar 4, 2023
- ||||| baxdrostat (CIN-107) / AstraZeneca
Clinical: Join @DLBHATTMD's presentation on the Results From a Phase 2, Double-Blind, Placebo-Controlled Trial (HALO) Evaluating the Efficacy and Safety of Baxdrostat In Patients With Uncontrolled Hypertension on March 4th, 12pm CT: https://t.co/rrWHZhvRSs #ACC23 #WCCardio #CardioTwitter (Twitter) - Mar 3, 2023
- ||||| baxdrostat (CIN-107) / AstraZeneca
Clinical: Join @DLBHATTMD's presentation on the Results From a Phase 2, Double-Blind, Placebo-Controlled Trial (HALO) Evaluating the Efficacy and Safety of Baxdrostat In Patients With Uncontrolled Hypertension on March 4th, 12pm CT: https://t.co/0USlfRRhx9 #ACC23 #WCCardio #CardioTwitter (Twitter) - Mar 3, 2023
- ||| baxdrostat (CIN-107) / CinCor Pharma
Clinical: In this RCT of 275 patients receiving 3 BP drugs (including a diuretic) & with a BP >130/80, 1mg & 2mg of baxdrostat (selective inhibitor of aldosterone) reduced systolic BP (least mean sqrs diff vs placebo at 12 weeks) by 8.1 & 11.0mmHg, respectively, https://t.co/tVHZbTwaeA (Twitter) - Feb 11, 2023
- | baxdrostat (CIN-107) / CinCor Pharma
Journal: Aldosterone synthase inhibitors and the treatment of essential hypertension. (Pubmed Central) - Feb 7, 2023
N=18 --> 12 | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 No abstract available
- || baxdrostat (CIN-107) / CinCor Pharma
Yeah - baxdrostat seems dead AFAIK https://t.co/oeLP6zDKHx They should have got someone else like @DrJMLuther to write the NEJM editorial (Twitter) - Feb 4, 2023
- | baxdrostat (CIN-107) / CinCor Pharma
In addition to lowering plasma aldosterone levels and blood pressure, baxdrostat had no substantive effect on plasma cortisol levels. 10/14 (Twitter) - Feb 3, 2023
- ||||| baxdrostat (CIN-107) / CinCor Pharma
Clinical: Phase 2 BrigHTN study: patients with treatment-resistant #hypertension who received #baxdrostat had dose-related reductions in #bloodpressure https://t.co/bMKOAeYZAb @DLBHATTMD #DataViz #visualabstract #HTN #CardioTwitter (Twitter) - Feb 2, 2023
- |||| baxdrostat (CIN-107) / CinCor Pharma
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension @NEJM Congrats @DLBHATTMD ! https://t.co/dfEre8gsUr (Twitter) - Feb 2, 2023
- | baxdrostat (CIN-107) / CinCor Pharma
Journal: Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors? (Pubmed Central) - Jan 20, 2023
No abstract available No abstract available
- baxdrostat (CIN-107) / CinCor Pharma
Results From A Phase 2, Double-blind, Placebo-controlled Trial Evaluating The Efficacy And Safety Of Baxdrostat In Patients With Uncontrolled Hypertension (Room 257; [In-Person]; [Virtual]; [Virtual On Demand]; [ACC Anywhere]) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7472;
No abstract available Abstract is embargoed at this time.
- PB6440 / PhaseBio Pharma
ENHANCED INHIBITION OF ALDOSTERONE PRODUCTION BY PB6440, A NOVEL AND VERY HIGHLY SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR (Pulmonary Vascular Disease, Valvular Heart Disease, Special Topics Moderated Poster Theater 4_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7187;
Here we compared PB6440 with baxdrostat and showed PB6440 was significantly more potent and selective than baxdrostat in vitro and in vivo. Baxdrostat had less than 100-fold selectivity for CYP11B2 vs. CYP11B1 compared to more than 300-fold selectivity with PB6440.
- || baxdrostat (CIN-107) / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - Jan 3, 2023
P2, N=300, Recruiting, Sponsor: CinCor Pharma, Inc.
Baxdrostat had less than 100-fold selectivity for CYP11B2 vs. CYP11B1 compared to more than 300-fold selectivity with PB6440. Trial completion date: Oct 2023 --> Aug 2024 | Trial primary completion date: Oct 2023 --> Aug 2024
- | baxdrostat (CIN-107) / CinCor Pharma
Journal: The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension. (Pubmed Central) - Dec 27, 2022
Trial completion date: Oct 2023 --> Aug 2024 | Trial primary completion date: Oct 2023 --> Aug 2024 No abstract available
- || baxdrostat (CIN-107) / AstraZeneca
Enrollment closed: Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 (clinicaltrials.gov) - Nov 21, 2022
P2, N=176, Active, not recruiting, Sponsor: CinCor Pharma, Inc.
No abstract available Recruiting --> Active, not recruiting
- | baxdrostat (CIN-107) / CinCor Pharma
【AHA 2022】BrigHTN試験より、治療抵抗性高血圧患者において、新規の選択的アルドステロン合成酵素阻害薬であるBaxdrostatにより用量依存的に血圧の低下が認められたことが発表された。 https://t.co/GjWpXObBOa #TCROSS #AHA2022 (Twitter) - Nov 17, 2022
- |||| baxdrostat (CIN-107) / AstraZeneca
Trial completion: HALO: A Study of CIN-107 in Patients With Uncontrolled Hypertension (clinicaltrials.gov) - Nov 15, 2022
P2, N=249, Completed, Sponsor: CinCor Pharma, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| baxdrostat (CIN-107) / CinCor Pharma
Clinical: BrigHTN: Baxdrostat showed dose-related reductions in blood pressure in patients with resistant hypertension compared to placebo Written by @lucas_marinacci! Summary and analysis and more #AHA22 coverage below: https://t.co/S77SwBkt0N @CMichaelGibson @leahkosyakovsky (Twitter) - Nov 9, 2022
- |||| baxdrostat (CIN-107) / CinCor Pharma
⭐️Selective inhibition of aldosterone synthase for hypertension. 🔺In preclinical and phase 1 studies, baxdrostat had 100:1 selectivity for enzyme inhibition. ✅Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension @NEJM https://t.co/SYwSl4fxtL (Twitter) - Nov 9, 2022
- ||| baxdrostat (CIN-107) / CinCor Pharma
A selective inhibitor of aldosterone synthase Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension | NEJM https://t.co/mSrEHrx7yE (Twitter) - Nov 8, 2022
- ||| baxdrostat (CIN-107) / CinCor Pharma
Clinical, Adverse events, Head-to-Head: I think there needs to be a head to head comparison of MRA versus baxdrostat to assess efficacy and differences in side effect profiles. Almost none of the patients prior to randomization were taking an MRA. (Twitter) - Nov 8, 2022
- || baxdrostat (CIN-107) / CinCor Pharma
P2 data, Journal: Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. (Pubmed Central) - Nov 8, 2022
P2
Patients with treatment-resistant hypertension who received baxdrostat had dose-related reductions in blood pressure. (Funded by CinCor Pharma; BrigHTN ClinicalTrials.gov number, NCT04519658.).
- |||| aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / CinCor Pharma
To sum up from session, 2 new promising Rx Aprocitentan and Baxdrostat👍. 2 are flopped. The RDN investigators pointed out the challenge of Covid on background Rx but all 4 trials are done the same time and face the same pandemic. Still unclear why office BP but 24ABP did not ⬇️ (Twitter) - Nov 7, 2022
- ||| spironolactone / Generic mfg., baxdrostat (CIN-107) / CinCor Pharma
Clinical: It also should be pointed out that none of patients are on spironolactone or MRA, I think that difference in cardiorenal outcomes are needed to inform the choice of baxdrostat vs MRA for (primary) resistant HTN (Twitter) - Nov 7, 2022
- |||| baxdrostat (CIN-107) / CinCor Pharma
Just published in @NEJM, a phase 2 trial of the aldosterone synthase inhibitor baxdrostat in resistant #hypertension that showed significant reductions in systolic and diastolic blood pressure with the highest dose tested: https://t.co/mglzlWnvPx (Twitter) - Nov 7, 2022
- ||||| firibastat (QGC-001) / Quantum Genomics, Biolab Pharma, Orient Europharma, aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / CinCor Pharma
Late-breaking abstract: Excited to moderate late breaking session with @DaichiShimbo on Nov7: 🆕Rx for resistant HTN. aminopeptidase-A inhibitor, firibastat, the dual ET antagonist aprocitentan, and selective aldosterone synthase inhibitor baxdrostat, and the highly anticipated results of RDN 📣 (Twitter) - Oct 30, 2022
- || baxdrostat (CIN-107) / CinCor Pharma
Clinical, P1 data, PK/PD data, Journal: Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. (Pubmed Central) - Oct 22, 2022
Baxdrostat was safe and well tolerated with a half-life that supports once-daily dosing. The dose-dependent reduction in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase.
- baxdrostat (CIN-107) / CinCor Pharma
Results From a Phase 1 Study Demonstrating the Safety and Pharmacokinetics of the Aldosterone Synthase Inhibitor CIN-107 in Subjects With Varying Degrees of Renal Function (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1618;
Renal impairment did not significantly impact systemic exposure or clearance of CIN-107, suggesting that dose adjustment due to PK differences in these patients is unnecessary, even in cases of advanced kidney disease. Plsma 107 Concentr vs Time
- ||| baxdrostat (CIN-107) / AstraZeneca
Enrollment closed: HALO: A Study of CIN-107 in Patients With Uncontrolled Hypertension (clinicaltrials.gov) - Oct 13, 2022
P2, N=248, Active, not recruiting, Sponsor: CinCor Pharma, Inc.
Plsma 107 Concentr vs Time Recruiting --> Active, not recruiting
- |||| aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / CinCor Pharma
Importantly, many LBCT on novel strategies for hypertension will be presented - BrigHTN: aldosterone synthase inhibitor baxdrostat - PRECISION: dual endothelin receptor antagonist aprocitentan - SPYRAL-HTN ON: renal denervation - FRSH: aminopeptidase-A inhibitor firabastat (Twitter) - Sep 24, 2022
- baxdrostat (CIN-107) / CinCor Pharma
Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension (Main Event I) - Sep 18, 2022 - Abstract #AHA2022AHA_6994;
Baxdrostat is the first aldosterone synthase inhibitor to demonstrate substantial lowering of BP without reducing serum cortisol levels. Its safe use, in combination with other inhibitors of the renin-angiotensin-aldosterone system, is anticipated to enhance protection against the deleterious effects of aldosterone on the cardiovascular system.
- firibastat (QGC-001) / Quantum Genomics, Biolab Pharma, Orient Europharma, aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / CinCor Pharma
LBS.09. Late-Breaking Science: Resistant HTN: A Pressure Cooker (Main Event I) - Sep 18, 2022 - Abstract #AHA2022AHA_6992;
The landscape of treatment options for resistant hypertension is expanding rapidly with the most recent clinical trials to prove it. This session includes the top line results of the first-in-class aminopeptidase-A inhibitor, firibastat (FRESH), the use of the dual endothelin receptor antagonist aprocitentan to affect underlying mechanisms for resistant HTN (PRECISION), the safety and efficacy of baxdrostat, a highly selective aldosterone synthase inhibitor (BrigHTN), and the anticipated results of radiofrequency renal denervation (SPYRAL HTN-ON).
- |||| baxdrostat (CIN-107) / AstraZeneca
Trial completion: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) - Sep 6, 2022
P2, N=348, Completed, Sponsor: CinCor Pharma, Inc.
This session includes the top line results of the first-in-class aminopeptidase-A inhibitor, firibastat (FRESH), the use of the dual endothelin receptor antagonist aprocitentan to affect underlying mechanisms for resistant HTN (PRECISION), the safety and efficacy of baxdrostat, a highly selective aldosterone synthase inhibitor (BrigHTN), and the anticipated results of radiofrequency renal denervation (SPYRAL HTN-ON). Active, not recruiting --> Completed